Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis.

It is important to note that the VisQoL was one of a battery of visual function and functional vision outcome measures used in this clinical trial, all of which together showed an overall trend of benefit from the Argus II system. 5 , 6 , 7 Conclusion The VisQoL was used to measure changes in utility scores in a rare population implanted with the Argus II retinal prosthesis system.

also in 4,871 other papers